Skip to Content

  • Search

View Additional Section Content

RTOG - 0831 - A Randomized, Double Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer

Objective

RATIONALE: Tadalafil may help prevent erectile dysfunction in patients with prostate cancer that has been treated with radiation therapy.  It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction.

PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy. 

(NCT00931528)

IRB Protocol Number
NCT00931528, RTOG - 0831

Clinical Trial Categories

  • Prostate Cancer
Contact
The Rosenfeld Cancer Center at 215-481-2402

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details